Clinical trials: Cancer: Solid Tumors
Advanced Solid Tumors
Phase 1 Trial of Oral Ixabepilone
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants…
- Trial name
- NCT00632424
- Testing
- Ixabepilone (oral formulation)
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- R-Pharm
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Advanced Solid Tumors
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually…
- Trial name
- NCT01999972
- Testing
- axitinib, crizotinib
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the effect of a single dose of 40 mg sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with advanced solid tumors.
- Trial name
- NCT02197572
- Testing
- Sapanisertib
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Calithera Biosciences, Inc
Advanced Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers…
- Trial name
- NCT02737475
- Testing
- BMS-986178, Nivolumab, Ipilimumab
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 166 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Advanced Solid Tumors
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.
- Trial name
- NCT02564900
- Testing
- DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)
- Where
- 14 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Solid Tumors
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of MK-4621 (RGT100) in adult…
- Trial name
- NCT03065023
- Testing
- MK-4621
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Solid Tumors
Phase I/Ib Multiple Ascending Dose Study in China
The purpose of this study was to evaluate the maximum tolerated dose (MTD) and pharmacokinetics (PK) of Avelumab monotherapy in Chinese subjects.
- Trial name
- NCT03523390
- Testing
- Avelumab 3 mg/kg Q2W, Avelumab 10 mg/kg Q2W, Avelumab 20 mg/kg Q2W
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors
Study of MLN8237 in Participants With Advanced Solid Tumors
The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on…
- Trial name
- NCT00962091
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Advanced Cancer
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan.
- Trial name
- NCT01347866
- Testing
- PF-05212384, PD-0325901, irinotecan
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
- Trial name
- NCT04616196
- Testing
- NKTR-255, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Advanced Malignancies
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.
- Trial name
- NCT00500903
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
- Trial name
- NCT00447005
- Testing
- Axitinib (AG-013736)
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Advanced Solid Tumours
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.
- Trial name
- NCT02341456
- Testing
- AZD1775, Paclitaxel, carboplatin
- Where
- 7 sites in Australia, Japan and 1 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Neoplasms
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts.
- Trial name
- NCT03447314
- Testing
- GSK1795091, GSK3174998, GSK3359609
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
This study is being done to investigate the safety, tolerability and anti-tumor activity of pembrolizumab (MK-3475) in participants with advanced triple negative breast cancer (TNBC) (Cohort A), advanced head and neck cancer…
- Trial name
- NCT01848834
- Testing
- Pembrolizumab
- Volunteers
- 297 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim